GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioventus Inc (NAS:BVS) » Definitions » Owner Earnings per Share (TTM)

Bioventus (Bioventus) Owner Earnings per Share (TTM) : -1.88 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bioventus Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Bioventus's Owner Earnings per Share (TTM) ended in Dec. 2023 was $-1.88. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Bioventus's Owner Earnings per Share (TTM) or its related term are showing as below:


During the past 9 years, the highest Price-to-Owner-Earnings ratio of Bioventus was 41.38. The lowest was 9.06. And the median was 35.14.


BVS's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 32.72
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Bioventus's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.09. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.51. It's PE Ratio ratio for today is At Loss.

Bioventus's EPS without NRI for the three months ended in Dec. 2023 was $-0.07. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.21. It's PE Ratio without NRI ratio for today is At Loss.


Bioventus Owner Earnings per Share (TTM) Historical Data

The historical data trend for Bioventus's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventus Owner Earnings per Share (TTM) Chart

Bioventus Annual Data
Trend Dec13 Dec14 Dec15 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only 0.25 1.27 0.35 -3.15 -1.88

Bioventus Quarterly Data
Mar16 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.15 -4.69 -4.38 -2.35 -1.88

Competitive Comparison of Bioventus's Owner Earnings per Share (TTM)

For the Medical Devices subindustry, Bioventus's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventus's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Bioventus's Price-to-Owner-Earnings falls into.



Bioventus Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Bioventus's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -156.2
Depreciation, Depletion and Amortization 57.4
Change In Deferred Tax -2.4
5Y Average of Maintenance Capital Expenditure 14.2
Change In Working Capital -3.2
Shares Outstanding (Diluted Average) 63.1

1. Start with "Net Income" from income statement. Bioventus's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-156.2 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Bioventus's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Dec. 2023 was $57.4 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Bioventus's Change In Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.4 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $14.2 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Bioventus's 5-Year Average Maintenance Capital Expenditure = $14.2 Mil

5. "Change In Working Capital" is from cashflow statement. Bioventus's Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.2 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Bioventus's Shares Outstanding (Diluted Average) for the months ended in Dec. 2023 was 63.106 Mil.

Bioventus's Onwer Earnings Per Share for Dec. 2023 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -156.23 +57.365+-2.377
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-14.167732601167+-3.181)/63.106
=-1.88

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=3.98/-1.88
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Bioventus Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Bioventus's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventus (Bioventus) Business Description

Traded in Other Exchanges
N/A
Address
4721 Emperor Boulevard, Suite 100, Durham, NC, USA, 27703
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in U.S and International markets.
Executives
Bihl Anthony P Iii director, officer: Interim CEO 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
John A. Bartholdson director, 10 percent owner C/O STONINGTON PARTNERS, INC., 540 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Juniper Investment Company, Llc 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022-3315
Katrina J Church officer: SVP & Chief Compliance Officer 3290 WEST BAYSHORE ROAD, PALO ALTO CA 94303
Alexis P Michas 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Juniper Targeted Opportunities, Lp 10 percent owner 555 MADISON AVENUE, 24TH FL, NEW YORK NY 10022
Juniper Targeted Opportunity Fund, L.p. 10 percent owner 555 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10022
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Mark Leonard Singleton officer: SEE REMARKS C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Anthony D'adamio officer: SVP & General Counsel C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Kenneth Michael Reali director, officer: Chief Executive Officer 5213 ATHERTON BRIDGE ROAD, RALEIGH NC 27613
John Nosenzo officer: Chief Commercial Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Alessandra Pavesio officer: SVP & Chief Science Officer C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gregory O. Anglum officer: SVP and CFO C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703

Bioventus (Bioventus) Headlines

From GuruFocus

Bioventus Completes Divestiture of its Wound Business

By sperokesalga sperokesalga 05-23-2023